Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.
Tojo A, Kyo T, Yamamoto K, Nakamae H, Takahashi N, Kobayashi Y, Tauchi T, Okamoto S, Miyamura K, Hatake K, Iwasaki H, Matsumura I, Usui N, Naoe T, Tugnait M, Narasimhan NI, Lustgarten S, Farin H, Haluska F, Ohyashiki K. Tojo A, et al. Among authors: iwasaki h. Int J Hematol. 2017 Sep;106(3):385-397. doi: 10.1007/s12185-017-2238-9. Epub 2017 Apr 25. Int J Hematol. 2017. PMID: 28444644 Clinical Trial.
Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia.
Yamauchi T, Mori Y, Miyamoto T, Kamezaki K, Aoki T, Yamamoto A, Takenaka K, Iwasaki H, Harada N, Nagafuji K, Teshima T, Akashi K. Yamauchi T, et al. Among authors: iwasaki h. Int J Hematol. 2009 Oct;90(3):416-420. doi: 10.1007/s12185-009-0405-3. Epub 2009 Aug 22. Int J Hematol. 2009. PMID: 19697098
Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation.
Uchida M, Ikesue H, Miyamoto T, Kato K, Suetsugu K, Ichinose K, Hiraiwa H, Sakurai A, Takenaka K, Muta T, Iwasaki H, Teshima T, Shiratsuchi M, Egashira N, Akashi K, Oishi R. Uchida M, et al. Among authors: iwasaki h. Biol Pharm Bull. 2013;36(5):819-24. doi: 10.1248/bpb.b12-01012. Biol Pharm Bull. 2013. PMID: 23649338 Free article.
Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.
Miyamoto T, Yoshimoto G, Kamimura T, Muta T, Takashima S, Ito Y, Shiratsuchi M, Choi I, Kato K, Takenaka K, Iwasaki H, Takamatsu Y, Teshima T, Akashi K. Miyamoto T, et al. Among authors: iwasaki h. Int J Hematol. 2013 Sep;98(3):337-45. doi: 10.1007/s12185-013-1402-0. Epub 2013 Jul 23. Int J Hematol. 2013. PMID: 23877150 Clinical Trial.
Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
Takashima S, Miyamoto T, Kadowaki M, Ito Y, Aoki T, Takase K, Shima T, Yoshimoto G, Kato K, Muta T, Shiratsuchi M, Takenaka K, Iwasaki H, Teshima T, Kamimura T, Akashi K. Takashima S, et al. Among authors: iwasaki h. Int J Hematol. 2014 Aug;100(2):159-64. doi: 10.1007/s12185-014-1611-1. Epub 2014 Jun 14. Int J Hematol. 2014. PMID: 24928523
A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial.
Ichinohe T, Kuroda Y, Okamoto S, Matsue K, Iida S, Sunami K, Komeno T, Suzuki K, Ando K, Taniwaki M, Tobinai K, Chou T, Kaneko H, Iwasaki H, Uemura C, Tamakoshi H, Zaki MH, Doerr T, Hagiwara S. Ichinohe T, et al. Among authors: iwasaki h. Exp Hematol Oncol. 2016 Apr 18;5:11. doi: 10.1186/s40164-016-0040-7. eCollection 2015. Exp Hematol Oncol. 2016. PMID: 27096106 Free PMC article.
High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura.
Takase K, Nagai H, Kadono M, Yoshioka T, Yoshio N, Hirabayashi Y, Ito T, Sawamura M, Yokoyama A, Yoshida S, Tsutsumi I, Otsuka M, Suehiro Y, Hidaka M, Yoshida I, Yokoyama H, Inoue H, Iida H, Nakayama M, Hishita T, Iwasaki H, Kada A, Saito AM, Kuroda Y. Takase K, et al. Among authors: iwasaki h. Int J Hematol. 2020 Mar;111(3):388-395. doi: 10.1007/s12185-019-02808-6. Epub 2020 Jan 2. Int J Hematol. 2020. PMID: 31897888
Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma.
Mori Y, Choi I, Yoshimoto G, Muta T, Yamasaki S, Tanimoto K, Kamimura T, Iwasaki H, Ogawa R, Akashi K, Miyamoto T; Fukuoka Blood and Marrow Transplantation Group. Mori Y, et al. Among authors: iwasaki h. Int J Hematol. 2020 May;111(5):673-680. doi: 10.1007/s12185-020-02833-w. Epub 2020 Jan 24. Int J Hematol. 2020. PMID: 31981096 Clinical Trial.
Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
Henzan H, Takase K, Kamimura T, Mori Y, Yoshimoto G, Iwasaki H, Nagafuji K, Ogawa R, Eto T, Uchida N, Fujisaki T, Kato K, Minami M, Kikushige Y, Akashi K, Miyamoto T; Fukuoka Blood & Marrow Transplantation Group (FBMTG). Henzan H, et al. Among authors: iwasaki h. Int J Hematol. 2020 Sep;112(3):349-360. doi: 10.1007/s12185-020-02911-z. Epub 2020 Jun 10. Int J Hematol. 2020. PMID: 32524309
2,426 results